Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study

Therapeutic Advances in Medical Oncology
Xue WangPeng Yuan

Abstract

Aromatase inhibitors (AIs) influence blood lipid profiles. However, relatively few studies have directly compared the treatment effects of steroidal and nonsteroidal AIs. A prospective single-center cohort study was conducted to investigate the effects of steroidal and nonsteroidal AIs on lipid profiles during the first 24 months of endocrine therapy in hormone receptor-positive postmenopausal patients with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, while the secondary endpoints were changes in lipid profiles and lipid event-free survival. Comparison of the lipid profiles of the two groups showed that triglycerides (TGs) and total cholesterol (TC) levels were significantly higher in the nonsteroidal AI group over 24 months (p < 0.05), whereas low-density lipoprotein cholesterol (LDL-C) was significantly higher only at 3 months (p = 0.017) and 6 months (p = 0.026). High-density lipoprotein cholesterol (HDL-C) was significantly lower in the steroidal group at all time points (p < 0.05), except at 18 months (p = 0.085). The cumulative incidence of lipid events in the steroidal and nonsteroidal groups at 24 months was 25.3% and 37.0%, respectively. Multivariate analysis results indicated...Continue Reading

References

Mar 17, 2001·JAMA : the Journal of the American Medical Association·R YancikJ W Yates
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen GeislerPer Eystein Lønning
Mar 12, 2004·The New England Journal of Medicine·R Charles CoombesUNKNOWN Intergroup Exemestane Study
Aug 16, 2005·British Journal of Cancer·N J Bundred
Dec 3, 2005·Cancer Research·Cynthia X MaRichard M Weinshilboum
Oct 9, 2007·Journal of the American College of Cardiology·Lee W JonesJohn R Mackey
Feb 19, 2008·The Breast : Official Journal of the European Society of Mastology·J C Doughty
Jan 8, 2010·Expert Opinion on Pharmacotherapy·Catherine M Kelly, Aman U Buzdar
Dec 17, 2011·Journal of Clinical Pharmacology·Lauren Nicole BellUNKNOWN Consortium on Breast Cancer Pharmacogenomics (COBRA)
Jul 18, 2012·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Dimitrios KoukourasGeorge Decavalas
Oct 24, 2012·Breast Cancer Research and Treatment·Kishor M WasanJames N Ingle
Jan 30, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul E GossLois E Shepherd
Apr 14, 2015·BioMed Research International·Seher BalabanAndrew J Hoy
Oct 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cesar A Santa-MariaUNKNOWN Consortium on Breast Cancer Pharmacogenomics (COBRA)
Apr 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Signe BorgquistBeat Thürlimann
Aug 24, 2017·Journal of Global Oncology·Ricardo L B Costa, William J Gradishar
Dec 19, 2017·Breast Cancer Research and Treatment·Marilyn L KwanJoan C Lo
Sep 29, 2018·Nature Communications·Christoph Nowak, Johan Ärnlöv

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

SPSS
GraphPad Prism

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.